tiprankstipranks
pc:viome

Viome

205 108th Ave NE Suite 150 Bellevue, Washington 98004, US
https://www.viome.com/
Viome is a leader in microbiome health science and personalized health solutions, focusing on revolutionizing early disease detection and preventative healthcare. The company aims to make illness optional by making early detection accessible to all, leveraging its innovative diagnostic technologies and expanding its offerings in the health sector.

Estimated Valuation

Leadership & Board

Current Number of Employees97
Current LinkedIn Followers21,118

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$25M
Total Amount Raised$25M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$25M
Latest Funding Amount$25M
Latest Funding RoundSeries D
Latest Funding RoundSeries D
Post-Money Valuation
Post-Money Valuation

Employee Trend

Viome had 97 employees as of September 7, 2026. The number of employees increased by 1 (1.04%) week-over-week.
97Latest Employee Count
1(1.04%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.

Social Trend

Viome had 21,118 followers as of September 7, 2026. The number of followers increased by 29 (0.14%) week-over-week.
21,118Latest Followers Count
29(0.14%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.

Main Enterprise Clients

A snapshot of major enterprise customers that use this private company’s products or services, highlighting its commercial reach and market adoption.

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Aug 14, 2025
Series D
$25.00M

Investors

Investor Name
Funding Round

Similar Companies

A snapshot of private companies similar to Viome, helping you discover and navigate related company profiles.

Related News and Analysis